In controlled trials in patients with plaque psoriasis, approximately 14.5% of patients treated with Enbrel developed injection site reactions compared with 5.2% of placebo-treated patients during the first 12 weeks of treatment.
Kontrollitud uuringutes psoriaasiga patsientidel tekkis esimese 12 ravinädala jooksul 14, 5% - l Enbreliga ravitud patsientidest süstekoha reaktsioon, võrrelduna 5, 2% - ga platseebot saanud patsientidest.